Prophylactic thyroidectomy in RET mutation carriers;Profylaktisk tyreoidektomi hos bærere av mutasjoner i RET-onkogenet

Tidsskrift for den Norske Laegeforening

Volumn 120, Issue 27, 2000, Pages 3249-3252

  Høie, Johan ^a   Heimdal, Ketil ^a   Nesland, Jahn M ^a   Børmer, Ole ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; MEDULLARY CARCINOMA; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEOTIDE SEQUENCE; SIPPLE SYNDROME; THYROID TUMOR; THYROIDECTOMY;

ADOLESCENT; ADULT; CARCINOMA, MEDULLARY; CHILD; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; ONCOGENE PROTEINS, FUSION; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0347116292     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Wells SA, Baylin SB, Leight GS, Dale JK, Dilley WG, Farndon JR. The importance of early diagnosis in patients with heriditary medullary carcinoma. Ann Surg 1982; 192: 595-9.
2. Calmettes C, Chaventre A, Feingold N, Franc B, Guliana JM. Screening for medullary thyroid cancer in France: a national effort. Henry Ford Hosp Med J 1989; 37: 120-1.
3. Simpson WJ, Carruthers JS, Malkin D. Results of a screening program for c-cell disease (medullary thyroid cancer and c-cell hyperplasia). Cancer 1990; 65: 1570-6.
4. Ponder BA, Ponder MA, Coffey R, Pembrey ME, Gagel RF, Telenius Berg M et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1988; 1: 397-400.
5. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-60.
6. Keller HD, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851-6.
7. Haugen DRF, Varhaug JE, Akslen LA, Lillehaug JR. Diagnostisk molekylær biologi ved solide svulster - thyreoidea. Tidsskr Nor Lægeforen 1998; 118: 2199-203.
8. Høie J, Jørgensen OG, Nesland JM, Møller P, Bjøro K. Medullært thyreoideakarsinom - familiær eller sporadisk sykdom? Tidsskr Nor Lægeforen 1994; 114: 2951-4.
9. Gautvik KM, Normann T, Teig V, Wille S, Brennhovd IO, Christensen I. Radioimmunoassay of human calcitonin in serum and tissue from healthy individuals and patients with medullary carcinoma of the thyroid gland. Scand J Clin Lab Invest 1976; 36: 323-9.
10. Motté P, Vaucelle P, Gardet P, Ghillani P, Caillou B, Parmentier C et al. Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal anti-peptide antibodies. Clin Chim Acta 1988; 174: 35-54.
11. Nicolli-Sire P, Murat A, Baudin F, Henry JF, Proye C, Bigorgne JC et al. Early or prophylactic thyroidectomy in MEN2/FMTC gene carriers: results in 71 thyroidectomized patients. The french calcitonin tumour study group (GETC). Eur J Endocrinol 1999; 141: 468-74.
12. Sikri KL, Varndell IM, Hamid QA, Wilson BS, Kameya T, Ponder BA et al. Medullary carcinoma of the thyroid. An immunocytochemical and histochemical study of 25 cases using eight separate markers. Cancer 1985; 56: 2481-91.
13. Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL et al. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin Endocrinol Oxf 1996; 44: 213-20.
14. Goodfellow PJ, Wells SA. RET gene and it implications for cancer. J Natl Cancer Inst 1995; 87: 515-23.
15. Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 1996; 381: 785-8.
16. Schuchardt A, D'Agati V, Blomberg LL, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994; 367: 380-3.
17. Decker RA, Peacock ML. Update on the profile of multiple endocrine neoplasia Type 2a RET mutations. Cancer 1997; 80: 557-67.
18. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994; 331: 828-35.
19. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996; 276: 1575-9.
20. Feldman GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG→ATG) mutation. Surgery 2000; 128: 93-8.